Drug Trial Radar · NCT03861273
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Actual
Start
Jul 29, 2019
Primary completion
Nov 16, 2022
Study completion Feb 25, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce genetic material into cells to compensate for missing or non-functioning Factor IX. Eligible study participants will have completed a minimum 6 months of routine Factor IX prophylaxis therapy during the lead in study (C0371004). Participants will be dosed once (intravenously) and will be evaluated over the course of 6 years. The main objective of the study will evaluate the annualized bleeding rate \[ABR\] for participants treated with gene therapy versus standard of care (SOC) therapy (FIX prophylaxis replacement regimen).
Conditions
- Hemophilia B
Interventions
PF-06838435/ fidanacogene elaparvovecBiological
Gene Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15Time frame: Pre-infusion period: minimum of 6 months through first dose of current study, an average of 1.31 years (FIX Prophylaxis arm); Week 12 to Month 15 post infusion in current study (PF-06838435 arm)
Locations
65 sites in 16 countries. Site status is shown where the registry gives one.
UCSF IDS Pharmacy
San Francisco, California
University of California, San Francisco - Clinical Research Center
San Francisco, California
University of California, San Francisco - Outpatient Hematology Clinic
San Francisco, California
The Regents of the University of California, San Francisco campus
San Francisco, California
Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus
Aurora, Colorado
Regents of the University of Colorado University of Colorado Denver, Office of Grants and Contracts
Aurora, Colorado
Indiana Hemophilia & Thrombosis Center, Inc.
Indianapolis, Indiana
Indiana Hemophilia and Thrombosis Center, Inc
Indianapolis, Indiana
Innovative Hematology, Inc.
Indianapolis, Indiana
St. Vincent Hospital & Health Care Center, Inc.
Indianapolis, Indiana
Madison Radiological Group
Madison, Mississippi
Mississippi Center for Advanced Medicine
Madison, Mississippi
Center for Human Phenomic Science
Philadelphia, Pennsylvania
Investigational Drug Service
Philadelphia, Pennsylvania
Penn Blood Disorder Center
Philadelphia, Pennsylvania
The Trustees of the University of Pennsylvania, Office of Clinical Research- Legal
Philadelphia, Pennsylvania
Royal Brisbane and Women's Hospital
Herston, Australia
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIO
Rio de Janeiro, Brazil
Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos - Hemoes
Vitória, Espírito Santo, Brazil
Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP
Campinas, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, São Paulo, Brazil
McMaster University Medical Centre - Hamilton Health Sciences
Hamilton, Ontario, Canada
Juravinski Hospital - Hamilton Health Sciences
Hamilton, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Hopital Cardiologique Louis Pradel - CRTH
Bron, France
Hopital Necker
Paris, France
Vivantes Klinikum Friedrichshain
Berlin, Germany
Vivantes Klinikum im Friedrichshain
Berlin, Germany
Universitätsklinikum Bonn Institut für Klinische Chemie und Klinische Pharmakologie -Phase 1-Einheit
Bonn, Germany
Universitätsklinikum Bonn, Anstalt des öffentlichen Rechts
Bonn, Germany
Universitätsklinikum Bonn
Bonn, Germany
General Hospital of Athens "LAIKO", 2nd Regional Blood Transfusion Center
Athens, Greece
Azienda Ospedaliero Universitaria Careggi
Florence, Italy
Azienda Ospedaliera Universitaria Federico II
Naples, Italy
Sapporo Tokushukai Hospital
Sapporo, Hokkaido, Japan
Nara Medical University Hospital
Kashihara, Nara, Japan
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.